The first bioanalogue of the original drug for the treatment of osteoporosis in Russia
17 April 2025
The first bioanalogue of the original drug for the treatment of osteoporosis in Russia has received a registration certificate from the Ministry of Health.
The active substance, the monoclonal antibody denosumab, prevents bone tissue degradation and helps increase bone mineral density.
The active substance, the monoclonal antibody denosumab, prevents bone tissue degradation and helps increase bone mineral density.
The effectiveness and safety of the drug «Forsedeno», produced by the company «Petrovax Pharm», was confirmed during the investigation. At this stage, more than 50 thousand patients suffering from osteoporosis have already undergone therapy.
The «Forcedeno» is planned to be supplied at a lower price compared to the cost of the original drug, which will have a positive impact on the availability of medical care.